Literature DB >> 29059173

SOX9 activity is induced by oncogenic Kras to affect MDC1 and MCMs expression in pancreatic cancer.

H Zhou1,2, Y Qin3,4, S Ji3,4, J Ling1, J Fu1, Z Zhuang1,5, X Fan1, L Song6, X Yu3,4, P J Chiao1,7.   

Abstract

SRY (sex determining region Y)-box 9 (SOX9) is required for oncogenic Kras-mediated acinar-to-ductal metaplasia (ADM), pancreatic intraepithelial neoplasias (PanINs) and ultimately pancreatic ductal adenocarcinoma (PDAC). However, how oncogenic Kras affects SOX9 activity is not yet understood, and SOX9-associated genes in PDAC are also unknown at all. Here, we investigated the mechanistic link between SOX9 and oncogenic Kras, studied biological function of SOX9, and identified SOX9-related genes and their clinical significance in patients with PDAC. Our studies reveal that oncogenic Kras induces SOX9 mRNA and protein expression as well as phosphorylated SOX9 expression in human pancreatic ductal progenitor cells (HPNE) and pancreatic ductal cells (HPDE). Moreover, oncogenic Kras promoted nuclear translocation and transcriptional activity of SOX9 in these cells. TAK1/IκBα/NF-κB pathway contributed to induction of SOX9 by oncogenic Kras, and SOX9 in turn enhanced NF-κB activation. SOX9 promoted the proliferation of HPNE and PDAC cells, and correlated with minichromosome maintenance complex components (MCMs) and mediator of DNA damage checkpoint 1 (MDC1) expression. The overexpressive MDC1 was associated with less perineural and lymph node invasion of tumors and early TNM-stage of patients. Our results indicate that oncogenic Kras induces constitutive activation of SOX9 in HPNE and HPDE cells, and Kras/TAK1/IκBα/NF-κB pathway and a positive feedback between SOX9 and NF-κB are involved in this inducing process. SOX9 accelerates proliferation of cells and affects MCMs and MDC1 expression. MDC1 is associated negatively with invasion and metastasis of PDAC.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29059173      PMCID: PMC6545484          DOI: 10.1038/onc.2017.393

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  39 in total

1.  KrasG12D-induced IKK2/β/NF-κB activation by IL-1α and p62 feedforward loops is required for development of pancreatic ductal adenocarcinoma.

Authors:  Jianhua Ling; Ya'an Kang; Ruiying Zhao; Qianghua Xia; Dung-Fang Lee; Zhe Chang; Jin Li; Bailu Peng; Jason B Fleming; Huamin Wang; Jinsong Liu; Ihor R Lemischka; Mien-Chie Hung; Paul J Chiao
Journal:  Cancer Cell       Date:  2012-01-17       Impact factor: 31.743

2.  Transcriptional up-regulation of Sox9 by NF-κB in endometrial carcinoma cells, modulating cell proliferation through alteration in the p14(ARF)/p53/p21(WAF1) pathway.

Authors:  Makoto Saegusa; Miki Hashimura; Erina Suzuki; Tsutomu Yoshida; Takeshi Kuwata
Journal:  Am J Pathol       Date:  2012-06-12       Impact factor: 4.307

3.  Identification of Sox9-dependent acinar-to-ductal reprogramming as the principal mechanism for initiation of pancreatic ductal adenocarcinoma.

Authors:  Janel L Kopp; Guido von Figura; Erin Mayes; Fen-Fen Liu; Claire L Dubois; John P Morris; Fong Cheng Pan; Haruhiko Akiyama; Christopher V E Wright; Kristin Jensen; Matthias Hebrok; Maike Sander
Journal:  Cancer Cell       Date:  2012-11-29       Impact factor: 31.743

4.  Beta-catenin blocks Kras-dependent reprogramming of acini into pancreatic cancer precursor lesions in mice.

Authors:  John P Morris; David A Cano; Shigeki Sekine; Sam C Wang; Matthias Hebrok
Journal:  J Clin Invest       Date:  2010-01-11       Impact factor: 14.808

5.  GSEA-P: a desktop application for Gene Set Enrichment Analysis.

Authors:  Aravind Subramanian; Heidi Kuehn; Joshua Gould; Pablo Tamayo; Jill P Mesirov
Journal:  Bioinformatics       Date:  2007-07-20       Impact factor: 6.937

6.  The nuclear factor-kappa B RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells.

Authors:  W Wang; J L Abbruzzese; D B Evans; L Larry; K R Cleary; P J Chiao
Journal:  Clin Cancer Res       Date:  1999-01       Impact factor: 12.531

7.  Novel SOX9 expression during human pancreas development correlates to abnormalities in Campomelic dysplasia.

Authors:  K Piper; S G Ball; J W Keeling; S Mansoor; D I Wilson; N A Hanley
Journal:  Mech Dev       Date:  2002-08       Impact factor: 1.882

8.  Cooperativity of oncogenic K-ras and downregulated p16/INK4A in human pancreatic tumorigenesis.

Authors:  Zhe Chang; Huaiqiang Ju; Jianhua Ling; Zhuonan Zhuang; Zhongkui Li; Huamin Wang; Jason B Fleming; James W Freeman; Dihua Yu; Peng Huang; Paul J Chiao
Journal:  PLoS One       Date:  2014-07-16       Impact factor: 3.240

9.  MDC1 Enhances Estrogen Receptor-mediated Transactivation and Contributes to Breast Cancer Suppression.

Authors:  Renlong Zou; Xinping Zhong; Chunyu Wang; Hongmiao Sun; Shengli Wang; Lin Lin; Shiying Sun; Changci Tong; Hao Luo; Peng Gao; Yanshu Li; Tingting Zhou; Da Li; Liu Cao; Yue Zhao
Journal:  Int J Biol Sci       Date:  2015-07-03       Impact factor: 6.580

10.  Upregulation of sex-determining region Y-box 9 (SOX9) promotes cell proliferation and tumorigenicity in esophageal squamous cell carcinoma.

Authors:  Yingcai Hong; Wen Chen; Xiaojun Du; Huiwen Ning; Huaisheng Chen; Ruiqing Shi; Shaolin Lin; Rongyu Xu; Jinrong Zhu; Shu Wu; Haiyu Zhou
Journal:  Oncotarget       Date:  2015-10-13
View more
  19 in total

Review 1.  Molecular signaling in pancreatic ductal metaplasia: emerging biomarkers for detection and intervention of early pancreatic cancer.

Authors:  Xiaojia Li; Jie He; Keping Xie
Journal:  Cell Oncol (Dordr)       Date:  2022-03-15       Impact factor: 6.730

Review 2.  Roles for MDC1 in cancer development and treatment.

Authors:  Sophie E Ruff; Susan K Logan; Michael J Garabedian; Tony T Huang
Journal:  DNA Repair (Amst)       Date:  2020-08-11

3.  Coumarin-Palladium(II) Complex Acts as a Potent and Non-Toxic Anticancer Agent against Pancreatic Carcinoma Cells.

Authors:  Aleksandra Krstic; Aleksandar Pavic; Edina Avdovic; Zoran Markovic; Milena Stevanovic; Isidora Petrovic
Journal:  Molecules       Date:  2022-03-25       Impact factor: 4.411

Review 4.  Fibroblast Growth Factor 10 in Pancreas Development and Pancreatic Cancer.

Authors:  Rodrick Ndlovu; Lian-Cheng Deng; Jin Wu; Xiao-Kun Li; Jin-San Zhang
Journal:  Front Genet       Date:  2018-10-29       Impact factor: 4.599

5.  miR-1-3p suppresses proliferation of hepatocellular carcinoma through targeting SOX9.

Authors:  Hao Zhang; Zhenya Zhang; Lili Gao; Zhengdong Qiao; Minghua Yu; Bo Yu; Tao Yang
Journal:  Onco Targets Ther       Date:  2019-03-22       Impact factor: 4.147

6.  Immune-related somatic mutation genes are enriched in PDACs with diabetes.

Authors:  Kaixuan Wang; Wei Zhou; Peng Meng; Peng Wang; Chunhua Zhou; Yao Yao; Shouxin Wu; Yu Wang; Jiangman Zhao; Duowu Zou; Gang Jin
Journal:  Transl Oncol       Date:  2019-06-13       Impact factor: 4.243

7.  LOTUS: A single- and multitask machine learning algorithm for the prediction of cancer driver genes.

Authors:  Olivier Collier; Véronique Stoven; Jean-Philippe Vert
Journal:  PLoS Comput Biol       Date:  2019-09-30       Impact factor: 4.475

8.  The overexpression of long intergenic ncRNA00162 induced by RelA/p65 promotes growth of pancreatic ductal adenocarcinoma.

Authors:  Yu Lu; Min Wu; Jie Fu; Yichen Sun; Kenei Furukawa; Jianhua Ling; Xue Qin; Paul J Chiao
Journal:  Cell Prolif       Date:  2020-05-04       Impact factor: 6.831

9.  SOX9 modulates cancer biomarker and cilia genes in pancreatic cancer.

Authors:  Hannah E Edelman; Sarah A McClymont; Tori R Tucker; Santiago Pineda; Rebecca L Beer; Andrew S McCallion; Michael J Parsons
Journal:  Hum Mol Genet       Date:  2021-04-30       Impact factor: 6.150

10.  Mitochondrial Protein UQCRC1 is Oncogenic and a Potential Therapeutic Target for Pancreatic Cancer.

Authors:  Qing Wang; Mengge Li; Yu Gan; Shuheng Jiang; Jie Qiao; Wei Zhang; Yingchao Fan; Yuling Shen; Yanfang Song; Zihong Meng; Ming Yao; Jianren Gu; Zhigang Zhang; Hong Tu
Journal:  Theranostics       Date:  2020-01-12       Impact factor: 11.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.